Journal
HYPERTENSION IN PREGNANCY
Volume 30, Issue 2, Pages 194-202Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/10641950903242675
Keywords
Plasminogen activator inhibitor-2; First-trimester screening; Preeclampsia; Uterine artery Doppler
Funding
- Fetal Medicine Foundation (UK Charity) [1037116]
- PerkinElmer, Inc., Wallac Oy, Turku, Finland
Ask authors/readers for more resources
Objective. In patients with preeclampsia maternal plasma concentration of plasminogen activator inhibitor-2 (PAI-2) is reduced. The objective of the study was to determine if the altered levels of PAI-2 precede the onset of the disease. Methods. Plasma PAI-2 was measured at 11-13 weeks of gestation in 119 pregnancies that developed preeclampsia, 85 that developed gestational hypertension and 204 controls. Results. There were no significant differences in PAI-2 between the preeclampsia, gestational hypertension and controls (1.07 MoM, 1.08 MoM and 0.96 MoM). Conclusion. The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available